Stock DNA
Pharmaceuticals & Biotechnology
USD 522 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.71
-79.13%
1.28
Revenue and Profits:
Net Sales:
1,395 Million
(Quarterly Results - Jun 2025)
Net Profit:
-104 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-40.27%
0%
-40.27%
6 Months
-67.94%
0%
-67.94%
1 Year
-64.16%
0%
-64.16%
2 Years
-94.57%
0%
-94.57%
3 Years
-95.94%
0%
-95.94%
4 Years
-97.0%
0%
-97.0%
5 Years
0%
0%
0.0%
Agilon Health, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
39.78%
EBIT Growth (5y)
2.55%
EBIT to Interest (avg)
-41.06
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.07
Sales to Capital Employed (avg)
7.79
Tax Ratio
0.70%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.79
EV to EBIT
-1.86
EV to EBITDA
-2.04
EV to Capital Employed
3.37
EV to Sales
0.09
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-180.74%
ROE (Latest)
-49.80%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 59 Schemes (74.44%)
Foreign Institutions
Held by 133 Foreign Institutions (8.52%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
1,395.00
1,532.80
-8.99%
Operating Profit (PBDIT) excl Other Income
-108.60
-14.70
-638.78%
Interest
1.60
1.50
6.67%
Exceptional Items
-0.10
-0.50
80.00%
Consolidate Net Profit
-104.40
-1.90
-5,394.74%
Operating Profit Margin (Excl OI)
-83.10%
-14.10%
-6.90%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -8.99% vs 0.68% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -5,394.74% vs 98.21% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
6,060.50
4,316.40
40.41%
Operating Profit (PBDIT) excl Other Income
-259.50
-211.80
-22.52%
Interest
6.20
6.70
-7.46%
Exceptional Items
-8.20
-0.20
-4,000.00%
Consolidate Net Profit
-250.30
-195.30
-28.16%
Operating Profit Margin (Excl OI)
-46.90%
-53.70%
0.68%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 40.41% vs 80.74% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -28.16% vs -111.59% in Dec 2023
About Agilon Health, Inc. 
Agilon Health, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






